Sentencing commission hears experts split on whether meth purity should drive punishments

The U.S. Sentencing Commission convened a public hearing focused on whether the guideline distinction that increases penalties for ‘‘actual’’ or ‘‘ice’’ methamphetamine versus ‘‘mixture’’ still matches how meth is produced, trafficked and used today. Chair Carlton W. Reeves opened the session saying, “Answering those question is why we are here today.”

Experts called to testify were sharply divided on whether purity remains a useful proxy for culpability. Drug Enforcement Administration witnesses and state and local law enforcement told commissioners that seized methamphetamine is now routinely extremely pure and that purity no longer reliably separates low‑level sellers from higher level traffickers. Jonathan Fairbanks, a DEA supervisory special agent, said in his testimony that his regional forensic data show seized methamphetamine “range between 78% to 98% with an overall purity mean of 87.46%” and that demand for high‑purity product has driven production methods toward industrial‑scale, high‑purity output. DEA forensic chief Scott Olten described laboratory burdens tied to isomer and purity testing, saying DEA analyzes roughly 16,000 meth exhibits per year and that conducting isomer/purity testing adds roughly 16,000 labor hours and about $740,000 annually in equipment and supplies.

State and local law enforcement echoed those observations. Mark Delaney of the Tennessee Bureau of Investigation told commissioners Tennessee routinely seizes meth “exceeding 90 plus percent” purity and said cartels now supply so much high‑purity product that lower level distributors commonly handle highly pure meth. Sergeant Timothy Williamson of the Ohio State Highway Patrol said Ohio labs and investigators see meth above 90% purity and warned that inconsistent federal and state charging approaches—for example, federal charging that weighs purity and federal mandatory minimums versus many state statutes that treat total weight—produce uneven punishments for essentially the same substance.

By contrast, academics and public‑health witnesses urged that purity is an outdated metric for sentencing. Behavioral scientist Dr. Carla Wagner described field research with people who use methamphetamine, reporting that typical users “do not choose their drugs based on purity” because nearly all product available is high purity; in her sample fentanyl appeared in only about 6% of meth samples and often reflected cross‑contamination. Operations and supply‑chain expert Dr. Jonathan Calkins argued that today’s market no longer shows the historical separation of high‑purity product for wholesalers and cut product for street sellers; the market now “sells just one kind of product,” he said, eroding the rational basis for different weight‑to‑penalty conversions.

Medical and treatment experts pressed commissioners to focus on frequency of exposure and co‑use rather than chemical purity. Addiction researchers, including Dr. Steven Shoptaw and Dr. Gavin Bart, summarized clinical and epidemiological evidence showing that repeated, high‑frequency use (for example, daily use) correlates with the most severe health outcomes—cardiovascular events, stroke, psychosis and pulmonary disease—whereas a single‑point purity measurement does not predict those harms. Clinical pharmacologists at the hearing emphasized that isomer testing (d versus l) affects potency but that users and purchasers typically titrate doses to achieve desired effects, meaning potency differences are often offset in real use.

Witnesses provided additional quantitative context that commissioners cited during Q&A. DEA and Customs data cited in testimony showed large nationwide seizures in 2024 and 2025 (Customs and Border Protection reported 54,769 kilograms seized so far in the current year and just over 79,000 kilograms in the prior year), and several law enforcement witnesses described sharp increases in methamphetamine seizure volumes in recent years. Price and quantity details given to the Commission varied by region: DEA and task force statements described a decline in wholesale prices and numerous accounts from researchers and users put street prices near $10–$20 per gram in some Western markets and bulk buys such as “7 grams for $50” in local studies.

Commissioners repeatedly asked panelists whether another marker—role in an organization, financial records, presence of weapons, number of people supervised—could replace purity as the sentencing proxy for culpability. DEA and many law enforcement witnesses replied that role‑based evidence and investigative findings about participation in trafficking organizations are the clearest indicators of higher culpability, but they also said such evidence is often harder to assemble than lab results. Academics and public‑health witnesses recommended expanding the guidelines’ emphasis on role and other case‑level aggravators and argued that relying on purity can produce arbitrary outcomes when a single commodity is uniformly high purity.

The hearing did not produce a vote or formal action; commissioners and staff indicated they will continue deliberations. Commissioners heard detailed operational concerns about lab backlogs, costs and the time it takes to run isomer/purity tests alongside repeated clinical testimony that frequency of exposure and polysubstance use (notably opioids and alcohol in many fatal cases) drive the most serious harms. Chair Reeves closed the panel with thanks to witnesses and staff and scheduled further work by Commission staff.

The hearing transcript and submitted written materials will be posted on the Commission website; commissioners said they will use the hearings, the written record and additional analyses to inform whether guideline language that treats ‘‘actual’’/‘‘ICE’’ differently from ‘‘mixture’’ should be revised.